ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > AAIC 2022 Promis Poster Embarrassment

<< Previous

Bullboard Posts

Next >>

Post by FarmerBettyon Aug 07, 2022 10:39pm

291 Views

Post# 34877793

AAIC 2022 Promis Poster Embarrassment

Must be embarrassing to be highlighting oligomer selectivity of PMN 310 at this conference? Repeating the same old message for 5-10 years, 50 times over. Bet they didn't have more than a handfull of people looking at this. It's so old. Two press releases shows how hard up they are too produce any meaning news.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals